Angiotensin II: Uses, Mechanism, and Side Effects

For patients in septic or distributive shock whose blood pressure will not stabilize, clinicians need agents that can raise it quickly. Angiotensin II is a hormone-based injectable approved for exactly this situation, used alongside other supportive care.

Key takeaways

• Angiotensin II Injection is approved to raise blood pressure in adults with septic or other distributive shock.
• It works by directly constricting blood vessels and increasing aldosterone release.
• The label does not carry a boxed warning.
• Over 880 clinical trials have been registered involving this compound or related research.
• FAERS reports most often mention drug ineffectiveness and complications associated with critical illness, reflecting the severity of the patients treated, not necessarily the drug itself.

What Angiotensin II Is

Angiotensin II belongs to the vasoconstrictor drug class. It raises blood pressure by binding to the angiotensin II receptor type 1 on vascular smooth muscle cells. This binding triggers a signaling cascade that causes the muscle in vessel walls to contract, narrowing the vessels and increasing aldosterone release, both of which push blood pressure upward.

What Angiotensin II Is Approved For

Angiotensin II Injection, marketed under the brand name Angiotensin II, is approved to increase blood pressure in adults with septic or other distributive shock. It functions as a vasoconstrictor used when blood pressure remains too low despite standard measures. No boxed warning is present on the label.

What the Evidence Shows

More than 880 trials in the clinical trials registry reference angiotensin II or related research areas. Among the sampled studies, a completed Phase 1 trial examined inherited variations in blood vessel receptors, directly relevant to how the drug's target functions. Other registered studies, such as a completed trial on antiseptic mouth rinses and an ongoing real-world evidence study of a cardiac monitoring device, illustrate the breadth of research activity captured under this compound's trial footprint, though they are not all direct efficacy studies of the drug itself.

Reported Side Effects

FDA Adverse Event Reporting System data include reports of drug ineffectiveness (71) and off label use (31) as the most common terms. Serious reports include death (26), acute kidney injury (25), toxicity to various agents (19), distributive shock (17), peripheral ischaemia (17), and hypotension (16). These are counts of submitted reports, not confirmed rates of incidence, and they do not establish that the drug caused the event. Because Angiotensin II is used in critically ill patients with shock, many reported outcomes likely reflect the underlying condition rather than the treatment.